VERAXA Biotech (NASDAQ: VRXA) announced the advancement of its bispecific antibody-drug conjugate (“bsADC”) program, VXA-222, after reaching a key technical milestone in its collaboration with OmniAb. The company said OmniAb has successfully completed its discovery work, allowing the program to move into its next phase. VXA-222 is designed to target two tumor antigens with a single molecule using an “AND-gate” approach intended to improve precision in treating solid tumors.
Under the collaboration launched in May 2025, OmniAb provided antibody discovery technologies, including its OmniClic™ platform, while VERAXA is applying its proprietary linker technology and conjugation expertise to develop and validate the lead bsADC candidate. VERAXA holds exclusive rights to develop and commercialize products arising from the collaboration, with OmniAb entitled to a share of specified revenue generated from resulting products.
The advancement of VXA-222 represents a significant step for VERAXA's pipeline of next-generation antibody-based therapeutics. The company is building a premier engine for the discovery and development of antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, VERAXA is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company's proprietary BiTAC® is a registered trademark of VERAXA Biotech GmbH.
This news is important because it highlights progress in the field of bispecific antibody-drug conjugates, a promising approach for treating solid tumors with greater specificity and reduced off-target effects. The successful completion of OmniAb's discovery work de-risks the program and paves the way for potential clinical advancement, which could lead to new treatment options for cancer patients.
For more details, the full press release is available at https://ibn.fm/qMRuJ. The latest news and updates relating to VRXA can be found in the company’s newsroom at https://ibn.fm/VRXA.
Forward-looking statements in this article involve risks and uncertainties, and actual results may differ materially. These statements are based on information available as of the date hereof, and the company undertakes no duty to update them unless required by law.
